42718-13-8

Basic information

• Product Name: alpha-AMino-4-fluorophenyl-acetic acid Methyl ester
• Synonyms: alpha-AMino-4-fluorophenyl-acetic acid Methyl ester;Methyl 2-aMino-2-(4-fluorophenyl)acetate;2-(4-Fluoro-phenyl)-DL-glycine Methyl ester HCl
• CAS NO: 42718-13-8
• Molecular Formula: C₉H₁₀FNO₂
• Molecular Weight: 183.1796032
• Mol File: 42718-13-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: alpha-AMino-4-fluorophenyl-acetic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: alpha-AMino-4-fluorophenyl-acetic acid Methyl ester(42718-13-8)
• EPA Substance Registry System: alpha-AMino-4-fluorophenyl-acetic acid Methyl ester(42718-13-8)

Safety Data

• Hazardous Substances Data: 42718-13-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 7292-73-1 (2RS)-N-(p-fluorophenyl)glycine 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 156276-23-2 methyl (p-fluorobenzoyl)formate 
• 403-32-7 (4-fluorophenyl)glyoxal 

Downstream Products

• 170902-74-6 (S)-methyl 2-amino-2-(4-fluorophenyl)acetate 
• 152121-61-4 4-[5-(4-fluoro-phenyl)-2-(4-methoxy-phenyl)-1H-imidazol-4-yl]-pyridine 
• 19883-57-9 (S)-2-amino-2-(4-fluorophenyl)acetic acid 
• 902133-70-4 methyl ({[(1-benzylpiperidin-4-yl)amino]carbonyl}amino)(4-fluorophenyl)acetate 
• 1190309-10-4 diethyl 1-acetyl-4'-(2-fluorophenyl)-5'-(4-nitrophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 
• 1190309-11-5 diethyl 1-acetyl-4'-(2-chlorophenyl)-5'-(4-nitrophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 
• 1190309-12-6 diethyl 1-acetyl-4'-(3-chlorophenyl)-5'-(4-nitrophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 
• 1190309-13-7 diethyl 1-acetyl-4'-(3,4-dichlorophenyl)-5'-(4-nitrophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 
• 1190309-14-8 diethyl 1-acetyl-4'-(naphthalen-2-yl)-5'-(4-nitrophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 
• 1190309-15-9 diethyl 1-acetyl-4'-(naphthalen-1-yl)-5'-(4-nitrophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 
• 1190309-16-0 diethyl 1-acetyl-4'-(furan-2-yl)-5'-(4-nitrophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 
• 1190309-17-1 diethyl 1-acetyl-5'-(4-nitrophenyl)-2-oxo-4'-styrylspiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 
• 1190309-18-2 diethyl 1-acetyl-4'-isobutyl-5'-(4-nitrophenyl)-2-oxospiro[indoline-3,3'-pyrrolidine]-2',2'-dicarboxylate 

Relevant articles and documents

A Structure?Activity Relationship Study of Novel Hydroxamic Acid Inhibitors around the S1 Subsite of Human Aminopeptidase N

Aminopeptidase N (APN/CD13) is a zinc-dependent ubiquitous transmembrane ectoenzyme that is widely present in different types of cells. APN is one of the most extensively studied metalloaminopeptidases as an anti-cancer target due to its significant role in the regulation of metastasis and angiogenesis. Previously, we identified a potent and selective APN inhibitor, N-(2-(Hydroxyamino)-2-oxo-1-(3′,4′,5′-trifluoro-[1,1′-biphenyl]-4-yl)ethyl)-4-(methylsulfonamido)benzamide (3). Herein, we report the further modifications performed to explore SAR around the S1 subsite of APN and to improve the physicochemical properties. A series of hydroxamic acid analogues were synthesised, and the pharmacological activities were evaluated in vitro. N-(1-(3′-Fluoro-[1,1′-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)-4-(methylsulfonamido)benzamide (6 f) was found to display an extremely potent inhibitory activity in the sub-nanomolar range.

Rh-catalyzed asymmetric hydrogenation of racemic aldimines via dynamic kinetic resolution

Catalyzed by a rhodium complex of P-stereogenic diphosphine ligand trichickenfootphos (TCFP), asymmetric hydrogenation of racemic aldimines via dynamic kinetic resolution has been realized for the preparation of chiral arylglycines with good yields and enantioselectivities.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula I: (where variables R1, R2, R3, R7, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache, and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.